Cargando…

Peroxisome Proliferator Activated Receptor-α Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice

The anti-inflammatory properties of PPAR-α plays an important role in attenuating hypertension. The current study determines the anti-hypertensive and anti-inflammatory role of PPAR-α agonist during a slow-pressor dose of Ang II (400 ng/kg/min). Ten to twelve week old male PPAR-α KO mice and their W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Justin L., Duan, Rong, El-Marakby, Ahmed, Alhashim, Abdulmohsin, Lee, Dexter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405818/ https://www.ncbi.nlm.nih.gov/pubmed/22848208 http://dx.doi.org/10.1155/2012/645969

Ejemplares similares

Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension
por: Lee, Dexter L., et al.
Publicado: (2011)

Peroxisome Proliferator-Activated Receptor α Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Angiotensin II-Induced ROS Production
por: Liu, Ye, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
por: Lee, Mi Young, et al.
Publicado: (2012)

Combination of a peroxisome proliferator‐activated receptor‐gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats
por: Shim, Chi Young, et al.
Publicado: (2013)

Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA/NaCl-Induced Hypertension in Female Rats
por: Dai, Shu-Yan, et al.
Publicado: (2016)

Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis
por: Katary, Mohamed A., et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor-Gamma Agonists Suppress Tissue Factor Overexpression in Rat Balloon Injury Model with Paclitaxel Infusion
por: Park, Jun-Bean, et al.
Publicado: (2011)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

378 Regulation of renal function by the peroxisome proliferator-activated receptor-alpha: A novel target for treating hypertension
por: Hatcher, Mark D, et al.
Publicado: (2023)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?
por: Gad, Hayam I.
Publicado: (2014)

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
por: Aljada, Ahmad, et al.
Publicado: (2009)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells?
por: Alsarra, Ibrahim A, et al.
Publicado: (2006)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
por: Alatas, Fatima Safira, et al.
Publicado: (2020)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats
por: Afzal, Sheryar, et al.
Publicado: (2020)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?
por: Freitag, Caroline M., et al.
Publicado: (2014)

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
por: Zhu, Yun-Xia, et al.
Publicado: (2016)

Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver
por: Ferguson, Laura B., et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization
por: Tobita, Yutaro, et al.
Publicado: (2020)

Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing
por: Tobita, Yutaro, et al.
Publicado: (2021)

Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
por: Miyachi, Hiroyuki
Publicado: (2021)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria
por: Garsen, Marjolein, et al.
Publicado: (2023)

Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis
por: Wei, Shuping, et al.
Publicado: (2020)

Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence
por: Matheson, Justin, et al.
Publicado: (2020)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction
por: Park, Jeong Rang, et al.
Publicado: (2016)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome Proliferator-Activated Receptor α Agonist and Its Target Nanog Cooperate to Induce Pluripotency
por: Lee, Jungwoon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_35bk15r13buil2j2317ii0pl31